权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Conjugation of anticancer drugs

抗癌药物的结合

基本信息

批准号：
7847471
负责人：
Swati Nagar
金额：
$ 7.5万
依托单位：
TEMPLE UNIV OF THE COMMONWEALTH
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-06-01 至 2012-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7847471
关键词：
AlamarBlue Antibodies Antineoplastic Agents Beta-glucuronidase Binding Biological Assay Biological Availability Breast Cancer Cell Caco-2 Cells Cell Death Cell Line Cell Proliferation Cells Chemicals Chemopreventive Agent Collaborations Colon Colorectal Cancer Complex Data Developed Countries Development Dietary Polyphenol Disease Drug Interactions Early Diagnosis Enzyme Kinetics Enzymes Estradiol Estrogens Evaluation Exhibits Future Glucuronidase Inhibitor Glucuronides Glucuronosyltransferase Goals HCT116 Cells HT29 Cells Hepatic Hepatocyte High Pressure Liquid Chromatography Human Incubated Inorganic Sulfates Intestines Isoenzymes Kinetics Knowledge Light Liver Malignant Neoplasms Measures Mediating Metabolism Minor Modeling Oral Parents Pharmaceutical Preparations Pharmacologic Substance Pharmacology Play Production Property Prostaglandin-Endoperoxide Synthase Proteins Rattus Regulation Reporting Research Resveratrol Rodent Model Role Science Screening procedure Steryl-sulfatase Testing Thapsigargin Therapeutic Effect Treatment Efficacy UGT1A1 gene Universities Unspecified or Sulfate Ion Sulfates Uridine Western Blotting Xenobiotics base colon cancer cell line colorectal cancer prevention compliance behavior dietary antioxidant drug development enzyme activity enzyme substrate fetal human tissue inhibitor/antagonist mortality polyphenol protein expression research study sulfation sulfotransferase trans-resveratrol treatment duration tumor

项目摘要

DESCRIPTION (provided by applicant): Colorectal cancer is a preventable yet highly prevalent disease worldwide. Poor patient compliance with screening procedures increases the mortality due to colorectal cancer. There is an urgent need for chemopreventive measures for this tumor type. One of the most promising chemopreventives in recent years is the dietary polyphenol resveratrol (RSV). While RSV has shown effective anticancer properties in cellular and rodent models, one limit to its development as a drug is its extremely high metabolism and resultant low oral bioavailability. There is ample evidence for therapeutic efficacy of RSV despite its high metabolism. The pharmacologic effects of RSV metabolites have never been elucidated. The overall goal of this proposal is to characterize the pharmacology of the major conjugated metabolites of RSV, and to delineate the effect of RSV on conjugating enzyme expression and activity. This research will advance our knowledge of a potential new chemopreventive drug, RSV, its pharmacology, and its potential for drug-drug interactions. We hypothesize that RSV conjugation plays an important role in its therapeutic effects via either inactivation or production of active metabolites. RSV is additionally hypothesized to alter its own conjugation by inhibition or induction of xenobiotic conjugating enzymes. Two specific aims are proposed: 1) Determine the pharmacologic activity of RSV conjugates, and 2) Characterize the effect of RSV on human uridine glucuronosyltransferase (UGT) and sulfotransferase (SULT) induction / inhibition. We will synthesize the major metabolites of RSV and test their role in cell proliferation with colon cancer cell lines (FHC controls, Caco-2, HT-29, and HCT-116) as our model. We will additionally evaluate changes in UGT / SULT protein expression and enzyme activity in human hepatocytes as well as colon cells upon treatment with RSV or its metabolites. Protein expression will be quantitated with western blot analysis, while enzyme activity will be characterized with specific substrates toward each isozyme. Taken together, these experiments will provide the first evaluation of the pharmacology of RSV metabolites, and the effect of RSV in regulation of enzymes responsible for its metabolism.

描述(由申请人提供)：结直肠癌是一种可预防但在全球范围内高度流行的疾病。患者对筛查程序的依从性差会增加结直肠癌的死亡率。迫切需要对这种类型的肿瘤采取化学预防措施。近年来最有前景的化学保护剂之一是膳食多酚白藜芦醇(RSV)。虽然RSV在细胞和啮齿动物模型中显示出有效的抗癌特性，但其作为药物开发的一个限制是其极高的新陈代谢和由此导致的低口服生物利用度。尽管RSV的新陈代谢很高，但有充分的证据表明它的治疗效果。RSV代谢物的药理作用从未被阐明。这项建议的总体目标是描述RSV主要结合代谢物的药理学特征，并描述RSV对结合酶表达和活性的影响。这项研究将促进我们对一种潜在的新的化学预防药物RSV的了解，它的药理作用，以及它在药物间相互作用中的潜力。我们推测，RSV的结合通过灭活或产生活性代谢物在其治疗效果中发挥重要作用。此外，RSV还被假设通过抑制或诱导异种结合酶来改变自己的结合。提出了两个具体目标：1)确定RSV结合物的药理活性；2)表征RSV对人尿苷葡萄糖醛酸基转移酶(UGT)和磺基转移酶(SULT)诱导/抑制的影响。我们将合成RSV的主要代谢物，并以结肠癌细胞系(FHC Controls、Caco-2、HT-29和HCT-116)为模型，测试它们在细胞增殖中的作用。此外，我们还将评估RSV或其代谢产物处理后人类肝细胞和结肠细胞中UGT/SULT蛋白表达和酶活性的变化。蛋白质的表达将通过蛋白质印迹分析来定量，而酶的活性将通过针对每种同工酶的特定底物来表征。综上所述，这些实验将首次评估RSV代谢物的药理学，以及RSV在调节负责其新陈代谢的酶方面的作用。